How to read a compounding vote

Compounding news travels fast and loses detail on the way. A few peptides in our index have been discussed at FDA advisory committee meetings about which bulk substances compounding pharmacies may use. A committee vote is a recommendation. The FDA makes the final call, and the two can differ.

When you see a headline, look for four things: the name of the substance, the specific list or category being discussed, what the committee actually voted, and whether the agency has issued a final decision. A vote to recommend is not an approval, and a vote against is not a ban on research.

We keep the status stamp on every sheet deliberately plain for this reason. “Not FDA-approved” is a fact about a drug pathway, not a verdict on the science, and the science is what the sheet is for.

Leans on the KPV sheet.

Sources

1. Regulator pagePharmacy Compounding Advisory Committee (opens in a new tab)US Food and Drug Administration. Meeting materials, votes, and minutes
2. Regulator pageBulk drug substances used in compounding under section 503A (opens in a new tab)US Food and Drug Administration. The lists and categories a vote can affect
3. Regulator statementCertain bulk drug substances for use in compounding that may present significant safety risks (opens in a new tab)US Food and Drug Administration, current as of April 2026

We link to the paper, the trial registry, or the regulator, never to a seller. A study type in the label tells you who or what was actually studied.

Spotted an error or a newer study? Tell the editors. Corrections are noted on the page. Our standards.

Education only. Not medical advice.